Literature DB >> 11221126

Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease.

A J Green1, G Giovannoni, M A Hall-Craggs, E J Thompson, R F Miller.   

Abstract

OBJECTIVES: To measure cerebrospinal fluid (CSF) tau in HIV infected patients with acute neurological episodes and to correlate the findings with the type and severity of neurological disease.
METHODS: CSF tau was prospectively measured in 76 consecutive HIV infected patients admitted to a specialist unit at UCL Hospitals, London, for investigation of acute neurological episodes: the results were compared with the clinical diagnoses.
RESULTS: 24 patients had HIV associated dementia complex (HADC), 10 had lymphoma (including four with primary CNS lymphoma), 20 had cerebral infections (including five with CMV encephalitis, five with VZV infection, seven with cryptococcal meningitis, two with toxoplasmosis, and one with progressive multifocal leucoencephalopathy); 22 patients had miscellaneous conditions, including nine with self limiting headache/fever. 62 patients (82%) had normal CSF tau concentration and 14 patients (18%) had elevated tau. In those with HADC, there was no correlation between the degree of dementia or atrophy on magnetic resonance imaging and CSF tau. Elevated CSF tau was associated with poor outcome as six of eight patients who died within 4 weeks of lumbar puncture had elevated tau (p = 0.0024, two tailed Fisher's exact test).
CONCLUSIONS: CSF tau levels are not elevated in the majority of HIV infected patients presenting with acute neurological episodes. CSF tau levels show no correlation with severity of dementia/atrophy on magnetic resonance imaging. Although elevated CSF tau was observed in some patients with conditions causing cerebral necrosis, the finding did not delineate underlying pathology but was associated with poor outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11221126      PMCID: PMC1744244          DOI: 10.1136/sti.76.6.443

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  16 in total

1.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

Authors:  A J Green; R J Harvey; E J Thompson; M N Rossor
Journal:  Neurosci Lett       Date:  1999-01-08       Impact factor: 3.046

2.  Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.

Authors:  B Giometto; S F An; M Groves; T Scaravilli; J F Geddes; R Miller; B Tavolato; A A Beckett; F Scaravilli
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

3.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Authors:  M Otto; J Wiltfang; H Tumani; I Zerr; M Lantsch; J Kornhuber; T Weber; H A Kretzschmar; S Poser
Journal:  Neurosci Lett       Date:  1997-04-11       Impact factor: 3.046

Review 4.  The AIDS dementia complex.

Authors:  R W Price; B J Brew
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

5.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

Authors:  D Galasko; C Clark; L Chang; B Miller; R C Green; R Motter; P Seubert
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

6.  Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.

Authors:  H Arai; Y Morikawa; M Higuchi; T Matsui; C M Clark; M Miura; N Machida; V M Lee; J Q Trojanowski; H Sasaki
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

7.  Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS.

Authors:  R F Miller; S B Lucas; M A Hall-Craggs; N S Brink; F Scaravilli; R J Chinn; B E Kendall; I G Williams; M J Harrison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

8.  Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia.

Authors:  I P Everall; J D Glass; J McArthur; E Spargo; P Lantos
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

9.  Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study.

Authors:  M J Harrison; S P Newman; M A Hall-Craggs; C J Fowler; R Miller; B E Kendall; M Paley; I Wilkinson; B Sweeney; S Lunn; S Carter; I Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

10.  Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC).

Authors:  R J Ellis; P Seubert; R Motter; D Galasko; R Deutsch; R K Heaton; M P Heyes; J A McCutchan; J H Atkinson; I Grant
Journal:  Neurosci Lett       Date:  1998-09-18       Impact factor: 3.046

View more
  18 in total

1.  Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Authors:  Magnus Gisslén; Jan Krut; Ulf Andreasson; Kaj Blennow; Paola Cinque; Bruce J Brew; Serena Spudich; Lars Hagberg; Lars Rosengren; Richard W Price; Henrik Zetterberg
Journal:  BMC Neurol       Date:  2009-12-22       Impact factor: 2.474

2.  Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection.

Authors:  Mihyun Bae; Neha Patel; Haoxing Xu; Mingwaoh Lee; Kumiko Tominaga-Yamanaka; Avindra Nath; Jonathan Geiger; Myriam Gorospe; Mark P Mattson; Norman J Haughey
Journal:  J Neurosci       Date:  2014-08-20       Impact factor: 6.167

Review 3.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

4.  HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau.

Authors:  Albert M Anderson; David Croteau; Ronald J Ellis; Debra Rosario; Michael Potter; Gilles J Guillemin; Bruce J Brew; Steven Paul Woods; Scott L Letendre
Journal:  J Neuroimmunol       Date:  2018-03-18       Impact factor: 3.478

5.  Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.

Authors:  Virawudh Soontornniyomkij; David J Moore; Ben Gouaux; Benchawanna Soontornniyomkij; Erick T Tatro; Anya Umlauf; Eliezer Masliah; Andrew J Levine; Elyse J Singer; Harry V Vinters; Benjamin B Gelman; Susan Morgello; Mariana Cherner; Igor Grant; Cristian L Achim
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

6.  Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.

Authors:  Sérgio Monteiro de Almeida; Clea E Ribeiro; Indianara Rotta; Mauro Piovesan; Bin Tang; Florin Vaida; Sonia Mara Raboni; Scott Letendre; Michael Potter; Meire S Batistela Fernandes; Ronald J Ellis
Journal:  J Neurovirol       Date:  2017-10-23       Impact factor: 2.643

7.  Markers of macrophage activation and axonal injury are associated with prospective memory in HIV-1 disease.

Authors:  Steven Paul Woods; Erin E Morgan; Jennifer Marquie-Beck; Catherine L Carey; Igor Grant; Scott L Letendre
Journal:  Cogn Behav Neurol       Date:  2006-12       Impact factor: 1.600

8.  Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.

Authors:  Radhika Adiga; Ahmet Y Ozdemir; Alexandra Carides; Melissa Wasilewski; William Yen; Pallavi Chitturi; Ronald Ellis; Dianne Langford
Journal:  J Neurovirol       Date:  2014-05-10       Impact factor: 2.643

Review 9.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

10.  CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.

Authors:  D B Clifford; A M Fagan; D M Holtzman; J C Morris; M Teshome; A R Shah; J S K Kauwe
Journal:  Neurology       Date:  2009-11-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.